Is the HLA-A2-restricted PSMA peptide LLHETDSAV poorly immunogenic in patients with metastatic prostate cancer?
Our results suggest that the PSMA peptide LLHETDSAV is poorly immunogenic in humans and that alternative prostate cancer antigens should be pursued.
Thus, relatively brief exposures to sidestream smoke early in life are sufficient to enhance arteriosclerotic plaque development.